Recent Press Releases

Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy (ipilimumab) Presented at the ESMO 2014 Congress; First Presentation of Phase 3 Results for a PD-1 Immune Checkpoint Inhibitor

Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy (ipilimumab) Presented at the ESMO 2014 Congress; First Presentation of Phase 3 Results for a...

Boehringer Ingelheim's afatinib achieves primary endpoint in global Phase III study in recurrent/metastatic head and neck squamous cell cancer

Boehringer Ingelheim's afatinib achieves primary endpoint in global Phase III study in recurrent/metastatic head and neck squamous cell cancer Results from the LUX-Head & Neck 1 study show...

GENENTECH'S PERJETA REGIMEN EXTENDED THE LIVES OF PEOPLE WITH AN AGGRESSIVE TYPE OF METASTATIC BREAST CANCER BY 15.7 MONTHS COMPARED TO HERCEPTIN AND CHEMOTHERAPY

GENENTECH'S PERJETA REGIMEN EXTENDED THE LIVES OF PEOPLE WITH AN AGGRESSIVE TYPE OF METASTATIC BREAST CANCER BY 15.7 MONTHS COMPARED TO HERCEPTIN AND CHEMOTHERAPY Final data from Phase III CLEOPATRA...

AMAG Pharmaceuticals to Acquire Lumara Health Maternal Health Business

AMAG Pharmaceuticals to Acquire Lumara Health Maternal Health Business Accelerates transformation of AMAG to a Profitable, Multi-Product Specialty Pharmaceutical Company Adds FDA-Approved Therapy...

Kamada Announces Second Extension of Strategic Agreement with Baxter

Kamada Announces Second Extension of Strategic Agreement with Baxter NESS ZIONA, Israel, Sep 29, 2014 (BUSINESS WIRE) -- Kamada Ltd. KMDA, +0.45% (tase:KMDA), a plasma-derived protein therapeutics...

ZYTIGA(R) Plus Prednisone Demonstrates Statistically Significant Overall Survival After 49-Month Follow-Up Analysis in Chemotherapy-Naïve Men with Metastatic Castration-Resistant Prostate Cancer

ZYTIGA(R) Plus Prednisone Demonstrates Statistically Significant Overall Survival After 49-Month Follow-Up Analysis in Chemotherapy-Naïve Men with Metastatic Castration-Resistant Prostate Cancer...

Release from Jackson Square Partners

IRVINE, Calif., Sept. 27, 2014 -- /PRNewswire/ -- Michael Gallagher, Lead Independent Director Allergan, Inc. 2525 Dupont Drive Irvine, CA 92612 Mr. Gallagher: We have owned Allergan...

Roche purchases shares in tender offer for InterMune, Inc.

BASEL, Switzerland, Sept.

Health Care Equipment Equities under the Scanner - Medtronic, Abbott Laboratories, Stryker, Zeltiq Aesthetics, and EnteroMedics

Editor Note: For more information about this release, please scroll to bottom.

LONDON, September 26, 2014

Abbott Completes Acquisition of CFR Pharmaceuticals; Announces Results of Tender Offer for CFR Shares

Acquisition enhances Abbott's position in Latin America, more than doubling its branded generics pharmaceutical sales and presence in the fast-growing region

ABBOT

Nintedanib* receives positive CHMP opinion for second-line treatment of patients with adenocarcinoma of the lung

Nintedanib* receives positive CHMP opinion for second-line treatment of patients with adenocarcinoma of the lung Nintedanib*, when added to docetaxel, is the first lung cancer treatment to have...

FDA Approves Trulicity™ (dulaglutide), Lilly's Once-Weekly Therapy for Adults with Type 2 Diabetes

FDA Approves Trulicity™ (dulaglutide), Lilly's Once-Weekly Therapy for Adults with Type 2 Diabetes Trulicity, a weekly glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for...

Valeant Provides Update On Third Quarter Results And Sends Letter To Allergan CEO And Lead Independent Director

Valeant Provides Update On Third Quarter Results And Sends Letter To Allergan CEO And Lead Independent Director Overall Same Store Organic Growth (unadjusted for generics) Expected to Exceed 15% in...

Jeffrey W. Ubben, CEO Of ValueAct Capital, Appointed To The Board Of Valeant Pharmaceuticals

Jeffrey W. Ubben, CEO Of ValueAct Capital, Appointed To The Board Of Valeant Pharmaceuticals LAVAL, Quebec, Sept. 25, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX)...

European CHMP Adopts Positive Opinion for Gilead's Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection in Adults

European CHMP Adopts Positive Opinion for Gilead's Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection in Adults FOSTER CITY, Calif., Sep 26, 2014 (BUSINESS WIRE)...

COMUNICADO: CHMP Recommends Approval of Lilly's Ramucirumab (CYRAMZA(TM)) for Advanced Gastric Cancer After Prior Chemotherapy (1)

COMUNICADO: CHMP Recommends Approval of Lilly's Ramucirumab (CYRAMZA(TM)) for Advanced Gastric Cancer After Prior Chemotherapy (1) Positive Opinion Is First Regulatory Action for Ramucirumab in...

Meeting highlights from the Committee for Medicinal Products for Human Use, 22-25 September 2014

Meeting highlights from the Committee for Medicinal Products for Human Use, 22-25 September 2014 Fifteen new medicines and three extensions of indication recommended for approval Fifteen new...

IRESSA RECEIVES CHMP POSITIVE OPINION TO INCLUDE BLOOD BASED DIAGNOSTIC TESTING IN EUROPEAN LABEL

IRESSA RECEIVES CHMP POSITIVE OPINION TO INCLUDE BLOOD BASED DIAGNOSTIC TESTING IN EUROPEAN LABEL 26 September 2014 AstraZeneca today announced that the Committee for Medicinal Products for Human Use...

MOVENTIG® (naloxegol) RECEIVES POSITIVE CHMP OPINION IN THE EU FOR THE TREATMENT OF ADULTS WITH OPIOID-INDUCED CONSTIPATION

MOVENTIG® (naloxegol) RECEIVES POSITIVE CHMP OPINION IN THE EU FOR THE TREATMENT OF ADULTS WITH OPIOID-INDUCED CONSTIPATION Friday, 26 September 2014 AstraZeneca today announced that the...

Novartis drug Signifor® LAR recommended by CHMP for EU approval to treat patients with rare hormonal disorder acromegaly

Novartis drug Signifor® LAR recommended by CHMP for EU approval to treat patients with rare hormonal disorder acromegaly Acromegaly is an endocrine disorder caused by elevated growth hormone (GH)...